Quantcast

Latest Ibritumomab tiuxetan Stories

2008-06-20 03:00:29

SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) held a Special Meeting in lieu of the Annual Meeting of Shareholders on Thursday, June 19, 2008 at its headquarters in Seattle. At the meeting, shareholders approved all matters with more than 95 percent of votes cast at the meeting voting in favor of each of the items proposed in the Company's Proxy Statement, including the reelection of directors Frederick Telling, M.D. Vartan Gregorian, Ph.D., and...

2008-06-18 12:01:00

Cell Therapeutics has signed an agreement with Bayer Schering Pharma to gain access to Bayer's Phase III Zevalin first-line Indolent trial data. The first-line Indolent trial (FIT), which evaluated the use of Zevalin as first-line consolidation therapy in follicular lymphoma patients, was sponsored by Bayer Schering Pharma, which has exclusive rights to Zevalin in all countries of the world except the US. CTI has now entered into an agreement with Bayer Schering Pharma to get access to this...

2008-06-18 03:00:07

SEATTLE, June 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) announced today an agreement with Bayer Schering Pharma to gain access to Bayer's phase III Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent Trial, FIT data. CTI expects that the data from the trial will be appropriate for CTI to begin discussions with the U.S. Food and Drug Administration (FDA) regarding the potential for a supplemental Biologics License Application (sBLA) for Zevalin...

2008-05-31 09:00:07

COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced results of a three-arm phase 3 clinical trial that show patients with relapsed and/or refractory mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, treated with the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) experienced a statistically significant improvement in median progression-free survival (PFS), compared with single-agent therapy...

2008-03-05 12:01:03

ROCHESTER, N.Y., March 5 /PRNewswire/ -- Vaccinex, Inc. announced today that Dr. John E. Leonard has joined its Scientific Advisory Board, and will be actively involved in the strategic planning and execution of the company's therapeutic antibody development programs. Dr. Leonard has over 20 years of experience at Idec and Biogen Idec, having held Senior Director level positions in Regulatory Affairs, Quality, Project Management and Product Development, and Vice President level positions...

2007-12-23 06:00:09

By Anonymous The U.S. Nuclear Regulatory Commission (NRC) announced in the Federal Register on October 24 that it had denied a petition for rulemaking (PRM35-19) originally submitted by William Stein, III, MD (Metairie, LA), on June 14, 2006. Stein had requested that the NRC amend Title 10 Code of Federal Regulations (CFR) 35 regulations governing training for parenteral administration of ^sup 153^Sm- lexidronam (Quadramet), ^sup 131^I-tositumomab (Bexxar), and ^sup 90^Y-ibritumomab...

2005-11-02 13:54:54

NEW YORK (Reuters Health) - New treatments incorporating immunotherapy - strategies that boost the immune system -- have significantly improved overall survival of patients with a blood cancer called follicular lymphoma, according to a new report. Emerging data suggest that for patients with follicular lymphoma "initial treatment choices may matter," Dr. Richard I. Fisher from University of Rochester in New York told Reuters Health. Fisher and colleagues compared outcomes of...

2005-06-20 21:47:54

TORONTO, Canada--Three scientific studies--each highlighting new discoveries in treatment for patients with non-Hodgkin's lymphoma--were announced at the Society of Nuclear Medicine's 52nd Annual Meeting June 18"“22 in Toronto. "Nuclear medicine has a growing role in treating non-Hodgkin's lymphoma," said SNM member Richard L. Wahl, M.D., director of nuclear medicine/PET at the Russell H. Morgan Department of Radiology and Radiological Science. "When nuclear medicine is used earlier in...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related